CA2896673A1 - Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii - Google Patents
Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii Download PDFInfo
- Publication number
- CA2896673A1 CA2896673A1 CA2896673A CA2896673A CA2896673A1 CA 2896673 A1 CA2896673 A1 CA 2896673A1 CA 2896673 A CA2896673 A CA 2896673A CA 2896673 A CA2896673 A CA 2896673A CA 2896673 A1 CA2896673 A1 CA 2896673A1
- Authority
- CA
- Canada
- Prior art keywords
- mal
- ppi
- iii
- dendrimer
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PLP.401934 | 2012-12-06 | ||
| PL401934A PL234887B1 (pl) | 2012-12-06 | 2012-12-06 | Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej |
| PCT/PL2013/000154 WO2014088434A1 (en) | 2012-12-06 | 2013-12-03 | Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2896673A1 true CA2896673A1 (en) | 2014-06-12 |
Family
ID=49955471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2896673A Abandoned CA2896673A1 (en) | 2012-12-06 | 2013-12-03 | Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20150320692A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2928478A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2016501260A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20150099539A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2013356792A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2896673A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL239143A0 (cg-RX-API-DMAC10.html) |
| PL (1) | PL234887B1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2014088434A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL234888B1 (pl) * | 2012-12-06 | 2020-04-30 | Univ Lodzki | Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090208580A1 (en) * | 2005-09-19 | 2009-08-20 | Regents Of The University Of Michigan | Functionalized dendrimer-encapsulated and dendrimer-stabilized nanoparticles |
| US20110177602A1 (en) * | 2007-06-27 | 2011-07-21 | Endress + Hauser Conducts Gesellschaft furMess-und Regeltechnik mbH +Co. KG | Composite Structure |
| PL234888B1 (pl) * | 2012-12-06 | 2020-04-30 | Univ Lodzki | Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej |
-
2012
- 2012-12-06 PL PL401934A patent/PL234887B1/pl unknown
-
2013
- 2013-12-03 AU AU2013356792A patent/AU2013356792A1/en not_active Abandoned
- 2013-12-03 KR KR1020157018092A patent/KR20150099539A/ko not_active Withdrawn
- 2013-12-03 WO PCT/PL2013/000154 patent/WO2014088434A1/en not_active Ceased
- 2013-12-03 US US14/650,458 patent/US20150320692A1/en not_active Abandoned
- 2013-12-03 EP EP13821003.4A patent/EP2928478A1/en not_active Withdrawn
- 2013-12-03 CA CA2896673A patent/CA2896673A1/en not_active Abandoned
- 2013-12-03 JP JP2015546418A patent/JP2016501260A/ja active Pending
-
2015
- 2015-06-02 IL IL239143A patent/IL239143A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016501260A (ja) | 2016-01-18 |
| PL234887B1 (pl) | 2020-04-30 |
| EP2928478A1 (en) | 2015-10-14 |
| US20150320692A1 (en) | 2015-11-12 |
| KR20150099539A (ko) | 2015-08-31 |
| IL239143A0 (en) | 2015-07-30 |
| AU2013356792A1 (en) | 2015-07-23 |
| PL401934A1 (pl) | 2014-06-09 |
| WO2014088434A1 (en) | 2014-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Zinc oxide nanoparticles induce human multiple myeloma cell death via reactive oxygen species and Cyt-C/Apaf-1/Caspase-9/Caspase-3 signaling pathway in vitro | |
| Hsin et al. | The apoptotic effect of nanosilver is mediated by a ROS-and JNK-dependent mechanism involving the mitochondrial pathway in NIH3T3 cells | |
| Shang et al. | Platelet-membrane-camouflaged black phosphorus quantum dots enhance anticancer effect mediated by apoptosis and autophagy | |
| Zhu et al. | Mitochondrion-targeted platinum complexes suppressing lung cancer through multiple pathways involving energy metabolism | |
| Liu et al. | Endothelial cells dysfunction induced by silica nanoparticles through oxidative stress via JNK/P53 and NF-κB pathways | |
| Zanotto-Filho et al. | The curry spice curcumin selectively inhibits cancer cells growth in vitro and in preclinical model of glioblastoma | |
| Manna et al. | RETRACTED ARTICLE: contribution of nano-copper particles to in vivo liver dysfunction and cellular damage: role of IκBα/NF-κB, MAPKs and mitochondrial signal | |
| Könczöl et al. | Cytotoxicity and genotoxicity of size-fractionated iron oxide (magnetite) in A549 human lung epithelial cells: Role of ROS, JNK, and NF-κB | |
| Yusuf et al. | Liposomal encapsulation of silver nanoparticles (AgNP) improved nanoparticle uptake and induced redox imbalance to activate caspase-dependent apoptosis | |
| Wu et al. | Vacuolization in cytoplasm and cell membrane permeability enhancement triggered by micrometer-sized graphene oxide | |
| Mameri et al. | Oxidative stress as an underlying mechanism of anticancer drugs cytotoxicity on human red blood cells' membrane | |
| Gui et al. | Nanoscale coordination polymer Fe-DMY downregulating Poldip2-Nox4-H2O2 pathway and alleviating diabetic retinopathy | |
| Zhang et al. | α-Santalol functionalized chitosan nanoparticles as efficient inhibitors of polo-like kinase in triple negative breast cancer | |
| Nie et al. | Selenium speciation-dependent cancer radiosensitization by induction of G2/M cell cycle arrest and apoptosis | |
| Knotigova et al. | Application of advanced microscopic methods to study the interaction of carboxylated fluorescent nanodiamonds with membrane structures in THP-1 cells: activation of inflammasome NLRP3 as the result of lysosome destabilization | |
| Ünsal et al. | The apoptotic effect of garlic (Allium sativum) derived SEVs on different types of cancer cell lines in vitro | |
| Makkar et al. | Molecular insight to size and dose-dependent cellular toxicity exhibited by a green synthesized bioceramic nanohybrid with macrophages for dental applications | |
| Su et al. | Roles of PTEN gene methylation in Se-CQDs induced mitochondrial apoptosis of osteosarcoma cells | |
| Gorojod et al. | Nanohydroxyapatite exerts cytotoxic effects and prevents cellular proliferation and migration in glioma cells | |
| US9877985B2 (en) | Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-OS-MAL-III | |
| US20150320692A1 (en) | Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii | |
| EP2788007B1 (en) | Use of silver(i) complexes as anticancer agents | |
| Zhang et al. | Sulforaphane Functionalized Chitosan Nanoparticles Serve as an Effective Nanocomplex System for the Treatment of Human Cervical Cancer: X. Zhang et al. | |
| US10022395B2 (en) | Application of maltotriose-coated 4th generation poly(propyleneimine) dendrimer PPI-G4-OS-Mal-III | |
| Jiang et al. | Iterative‐Designed Multifunctional Carbon Dots Nanodrug for Celastrol Loading, Targeting Delivery, and Combination Therapy of Kidney Stones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20191203 |